Company Background

Immuron has developed a GMP (Good Manufacturing Practice) compliant production system that produces hyper-immune bovine colostrum powder (BCP) suitable for use as pharmaceuticals. This production system is the result of a significant body of know-how that Immuron developed over the years and is reflected in its standard operating protocols as well as aspects of the production system that are patented. The production system is capable of producing and has in fact already generated many tonnes of hyper-immune bovine colostrum powder. These large amounts of BCP can be generated within approximately 4 months.

Since the Company’s inception in 1994, a considerable amount of work has led both to a greater understanding of the science underpinning the products and to optimization of the technology platform. Originally, Immuron’s focus was on the research and development of products to prevent a range of infectious diseases.

In 2009 the Company entered into a collaboration with the Hadassah Medical Center Israel, through Hadasit Medical Research Services and Development Limited, Hadassah’s commercialisation company. Through Hadassah’s broad ranging expertise Immuron is now also focused a range of chronic diseases such as liver disease, diabetes and other large target markets.

Through its partnership with Hadassah, Immuron also significantly bolstered its research and development capabilities. The Company has direct access to the Good Clinical Practice (GCP) compliant clinical trials unit at Hadassah Medical Center as well as its animal model laboratories. The team at Hadassah has already established clinical proof of concept for Immuron product candidate that targets Non-Alcoholic Steatohepatitis (NASH).